Pre-clinical screening of drugs using the mdx mouse

Neuromuscular Disorders

Volumn 10, Issue 4-5, 2000, Pages 235-239

  Granchelli, Joseph A ^a   Pollina, Catherine ^a   Hudecki, Michael S ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

mdx; Mouse; Muscular dystrophy; Therapeutic evaluation; Therapy

Indexed keywords

ALANINE; AMINO ACID; CALPASTATIN; CREATININE; CYCLOSPORIN; CYSTEINE; DYSTROPHIN; EBSELEN; GLUTAMINE; HEME ARGINATE; HUMAN GROWTH HORMONE; IBUPROFEN; LYSINE; OXATOMIDE; PARACETAMOL; PENTOXIFYLLINE; PEPSTATIN; PREDNISONE; RECOMBINANT SOMATOMEDIN C; SERINE; SOMATOMEDIN C;

ANIMAL MODEL; ARTICLE; FEMALE; MALE; MOUSE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; MALE; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 0034214278     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(99)00126-1     Document Type: Article

References (33)

1. Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) CDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50:509-517.
2. Huffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
3. McArdle A, Edwards RHT, Jackson MJ. Effects of contractile activity on muscle damage in the dystrophin deficient mdx mouse. Clin Sei 1991;180:367-371.
4. McNeil PL, Khakee R. Disruptions of muscle fiber plasma membranes: role of exercise-induced damage. Am J Pathol 1992; 140:1097-1109.
5. Moens P, Baatsen PHWW, Marechal G. Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J Muscle Res Cell Motil 1993;14:446-451.
6. Baloh R, Cancilla PA, Kalyanaraman K, et al. Regeneration in human muscle. Lab Invest 1972;26:319-328.
7. Dubowitz V, Brooke MH. Muscle biopsy: a modern approach. 2nd ed.. London: W.B. Saunders, 1973.
8. Bourne GH, Golarz MN. Human muscular dystrophy as an aberration of the connective tissue. Nature 1959;183:1741-1743.
9. Cazzato G. Considerations about a possible role played by connective tissue proliferation and vascular disturbances in the pathogenesis of progressive muscular dystrophy. Eur Neurol 1968;1:158-179.
10. Duance VC, Stephens HR, Dunn M, et al. A role for collagen in the pathogenesis of muscular dystrophy. Nature 1980;284:470-472.
11. D'Amore PA, Brown R, Ku PT, et al. Elevated levels of bFGF in the serum of patients with Duchenne muscular dystrophy. Ann Neurol 1994;35:362-365.
12. Helliwell TR, Gunhan O, Edwards RHT. Mast cells in neuromuscular diseases. J Neurol Sci 1990;98:267-276.
13. Gorospe JRM, Tharp MD, Hinckley J, et al. A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs and mice. J Neurol Sci 1994;122:44-56.
14. Schmalbruch H. Segmental fiber breakdown and defects of the plas-malemma in diseased human muscles. Acta Neuropathol (Berlin) 1975;33:129-141.
15. Mokri B, Engel AG. Duchenne dystrophy: electron microscopic findings point to an early abnormality in the plasma membrane of the muscle fiber. Neurology 1975;25:1111-1120.
16. Drachman DB, Toyka KB, Meyer E. Prednisone in muscular dystrophy. Lancet 1974;2:1409-1412.
17. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation of Duchenne muscular dystrophy: interesting results of a trial of predni-sone. Arch Neurol 1987;44:812-817.
18. Desilva S, Drachman DB, Mellits D, et al. Prednisone treatment in Duchenne muscular dystrophy: long term benefit. Arch Neurol 1987;44:818-822.
19. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-1597.
20. Griggs RC, Moxiey RT, Mendel JR, et al. A comparison of daily and alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991;48:575-579.
21. Griggs RC, Moxiey RT, Mendell JR, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Arch Neurol 1991;48:383-388.
22. Griggs RC, Moxley RT, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azothioprine. Neurology 1993;43:520-527.
23. Sugita H, Arahata K, Ishiouro T, et al. Negative immunostaining of Duchenne muscular dystrophy (DMD) and mdx muscle surface membrane with antibody against synthetic peptide fragment predicted from DNM cDNA. Proc Jpn Acad 1988;64:37-39.
24. Sicinski P, Geng Y, Ryder-Cook AS, et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989;244:1578-1580.
25. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51(4):919-928.
26. Tanabe Y, Esaki K, Nomura T. Skeletal muscle pathology in x chromosome-linked muscular dystrophy (mdx) mouse. Acta Neuropathol (Berlin) 1986;69:91-95.
27. Coulton RG, Morgan JE, Partridge TA, et al. The mdx mouse skeletal muscle myopathy: I. A histopathological, morphometric and biochemical investigation. Neuropathol Appl Neurobiol 1988; 14:53-70.
28. Cooper BJ. Animal models of Duchenne and Becker muscular dystrophy. Br Med Bull 1989;45:713-718.
29. Hudecki MS, Pollina CM. Mdx mouse as therapeutic model system: development and implementation of phenotypic monitoring. In: Griggs RC, Karpati G, editors. Myoblast transfer, New York: Plenum Press, 1990. pp. 251-263.
30. Hudecki MS, Pollina CM, Granchelli JA, et al. Strength and endurance in the therapeutic evaluation of prednisolone-treated mdx mice. Res Commun Chem Pathol Pharmacol 1993;79:45-60.
31. [31 ] Granchelli JA, Hudecki MS, Pollina CM. Enhanced sensitivity of mdx mice to intramuscular injection of compound 48/80. Res Commun Chem Pathol Pharmacol 1994;84(3):351-362.
32. Gorospe JRM, Nishikawa B, Hoffman EP. Recruitment of mast cells to muscle after mild damage. J Neurol Sci 1996;135:10-17.
33. Jurasinski CV, Vary TC. Insulin-like growth factor I accelerates protein synthesis in skeletal muscle during sepsis. Am J Physiol EndocrMetab 1995;269:E977-E981.